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Nicolas Blondeau, Catherine Widmann, Michel Lazdunski, and Catherine Heurteaux
Institut de Pharmacologie Mole´culaire et Cellulaire, Centre National de la Recherche Scientifique, Unite´ Mixte de
Recherche 6097, Sophia Antipolis, 06560 Valbonne, France
The transcription factor nuclear factor-kB (NFkB) is an ubiqui-
tously expressed inducible regulator of a broad range of genes
and plays a pivotal role in cell death and survival pathways.
Three models of brain tolerance (ischemic, epileptic, and poly-
unsaturated fatty acid-induced preconditioning), known to con-
fer resistance to neurons against ischemia or status epilepticus,
were used to determine whether NFkB mediated the late pre-
conditioning. A sublethal 3 min ischemia, a dose of 5 mg/kg
kainic acid (KA5) or 500 nmol of linolenic acid (LIN500) led to a
rapid increase of NFkB DNA-binding activity and nuclear trans-
location of p65 and p50 subunits of NFkB in neurons. Pretreat-
ment with the NFkB inhibitor diethyldithiocarbamate or kB
decoy DNA blocked the increased DNA-binding activity and the
nuclear translocation of NFkB and abolished the neuroprotec-
tive effects of different delayed preconditionings against severe
ischemia or epilepsy. The inhibition of NFkB observed in rats
preconditioned with 3 min ischemia, KA5 or LIN500 treatments
compared with ischemic or epileptic controls was correlated
with the prevention of the inducible degradation of the inhibitory
protein IkBa. Preconditioning probably inhibits the activation of
NFkB by interfering with a pathway that leads to the direct
transcriptional activation of IkBa by NFkB itself. The present
work provides evidence that activation of NFkB is a crucial step
in the signal transduction pathway that underlies the develop-
ment of brain tolerance and may open new strategies in the
prevention of cerebral diseases, such as ischemia or epilepsy.
Key words: NFkB; brain preconditioning; ischemia; kainic
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Noxious stimuli applied at doses close to but below the threshold
of cell injury induce adaptative responses that protect the brain
against additional stress from the same (tolerance) or other
(cross-tolerance) stimuli. Among different stresses, hypoxia (Gid-
day et al., 1994), ischemia (Kitagawa et al., 1990; Kirino et al.,
1991; Liu et al., 1992; Simon et al., 1993; Glazier et al., 1994;
Heurteaux et al., 1995; Matsushima and Hakim, 1995; Toyoda et
al., 1997), seizures (Plamondon et al., 1999), anoxia (Perez-
Pinzon et al., 1996), spreading depression (Kawahara et al., 1994;
Matsushima et al., 1996), heat (Chopp et al., 1989; Kitagawa et
al., 1991b), oxidative stress (Ohtsuki et al., 1992), polyunsaturated
fatty acids (PUFAs) treatment (our unpublished data), and in-
hibitors of oxidative phosphorylation (Riepe et al., 1997) induce
tolerance to subsequent cerebral (focal or global) ischemia. Sim-
ilarly, kainic acid (KA)- or bicuculline-induced seizures and
hippocampal kindling reduce the injurious impact of a second
epileptic challenge (Kelly and McIntyre, 1994; Sasahira et al.,
1995; Plamondon et al., 1999). The existence of early and delayed
phases of preconditioning against brain injuries is now as well
established as it is in cardiac preconditioning (Millar et al., 1996).
Clearly, the first phase occurs within minutes and is transient
(Perez-Pinzon et al., 1997), whereas the delayed phase takes
hours to become apparent and lasts for days (Kitagawa et al.,
1990; Kirino et al., 1991). Recent studies show that the initial
signals responsible for triggering the development of both pre-
conditionings involve the opening of ATP-sensitive K1 channels
(KATP channels) via the activation of adenosine A1 receptors
(Heurteaux et al., 1995; Reshef et al., 1998a,b; Plamondon et al.,
1999; Blondeau et al., 2000). However, delayed preconditioning
requires de novo synthesis of proteins, promoting neuronal sur-
vival, including heat shock protein 70 (Kitagawa et al., 1990,
1991a; Liu et al., 1993; Nishi et al., 1993; Simon et al., 1993;
Blondeau et al., 2000), Bcl-2 (Shimazaki et al., 1994), and super-
oxide dismutase (MnSOD) (Toyoda et al., 1997). It seems likely
that the signaling pathway of late preconditioning would include
the activation of transcription factors that drive the expression of
proteins responsible for neuroprotection.
One of the transcription factors that could activate gene ex-
pression in response to epileptic or ischemic preconditioning is
the nuclear factor-kB (NFkB). This oxidative responsive tran-
scription factor plays a pivotal role in neuronal survival and
plasticity (for review, see Mattson et al., 2000). NFkB is activated
by various intercellular signals, including cytokines, neurotrophic
factors, and neurotransmitters. Oxidative stress and elevation of
intracellular calcium levels are particularly important inducers of
NFkB activation. Stimulation of glutamate receptors and mem-
brane depolarization lead to activation of NFkB in hippocampal
pyramidal neurons and cerebellar granule neurons (Guerrini et
al., 1995; Kaltschmidt et al., 1995). NFkB activity is increased in
neurons and glial cells in both neurodegenerative disorders
(Hunot et al., 1997; Kaltschmidt et al., 1997; Lukiw and Bazan,
1998) and models of stroke, cardiac arrest, or epilepsy (Rong and
Baudry, 1996; Clemens et al., 1997; Gabriel et al., 1999). The
involvement of NFkB in the inhibition of apoptosis is now well
established (Mattson et al., 2000). NFkB plays a central role in
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the induction of neuroprotective antiapoptotic gene products,
such as MnSOD and Bcl-2 that are known to contribute to
ischemic tolerance (Toyoda et al., 1997). NFkB is made up of two
prototypical subunits of 50 kDa (p50) and 65 kDa (p65; RelA)
that belong to the Rel family. The most usual form of NFkB is a
heterodimer of p65 and p50, which normally exists in the cyto-
plasm in a dormant form bound to one of a member of inhibitory
proteins called IkBa, IkBb, IkBe, p105, and p100 (for review, see
Verma et al., 1995; Baeuerle and Baltimore, 1996). During acti-
vation, NFkB dissociates from Ikb and translocates as a p50/p65
dimer to the nucleus as a result of the complete proteolytic
degradation of Ikb proteins or the partial degradation of p105
and p100 precursors. Phosphorylation by a protein kinase com-
plex Ikb kinase and ubiquitination of Ikb are necessary for
dissociation of Ikb from the transcription dimer, which binds to
consensus kb sequences in the enhancer region of kb-responsive
genes and then can initiate gene transcription (Chen et al., 1995;
Verma et al., 1995; Baeuerle and Baltimore, 1996).
The purpose of the present study is to test the hypothesis that
the delayed preconditioning is mediated by NFkB and to charac-
terize the mechanisms that trigger the translocation of NFkB
during preconditioning in three models of brain tolerance (isch-
emic, epileptic, and polyunsaturated fatty acid-induced precondi-
tioning) known to confer resistance to hippocampal neurons
against neuronal injury associated with ischemia or status
epilepticus.
MATERIALS AND METHODS
Animals. Experiments were performed on male Wistar rats weighing
250–300 gm (Charles River Laboratories, St. Aubin, France). The ani-
mals, maintained on a 12 hr light /dark cycle, were given food and water
ad libitum. They were acclimatized for at least 1 week before drug
treatments or surgery. All animal experiments were performed in accor-
dance with NIH Guide for the Care and Use of Laboratory Animals. All
efforts were made to minimize the number of animals used and their
suffering.
Preconditioning procedures. Two different paradigms of brain injury
were used: the four-vessel occlusion model of transient global forebrain
ischemia (Pulsinelli and Brierley, 1979) and KA-induced (seizure-
mediated) excitotoxic damage (Lothman and Collins, 1981) to hip-
pocampal neurons. Vehicle-injected or sham-operated rats were used as
negative controls for ischemia and epilepsy. Preconditioned groups were
as follows. Ischemic preconditioned rats received a 3 min sublethal global
ischemia (I3) before severe 6 min ischemia (I6); KA5-preconditioned
animals were intraperitoneally injected with a 5 mg/kg dose of KA 3 d
before a second KA7.5 challenge (7.5 mg/kg). PUFA-preconditioned rats
were intravenously injected with linolenic acid (LIN500, 500 nmol/kg
body weight) 3 d before KA7.5 injection or 6 min ischemia. Vehicle-
injected or sham-operated animals treated 3 d before KA7.5 injection or
6 min ischemia were used as controls for the preconditioned groups. Rats
were killed at 1, 24, and 72 hr after the last treatment (n 5 6 per time per
group).
Transient complete forebrain ischemia. Transient complete forebrain
ischemia was performed by four-vessel occlusion as described previously
(Pulsinelli and Brierley, 1979; Heurteaux et al., 1995). Briefly, rats were
deeply anesthetized by inhalation of 2% halothane mixed with 30%
oxygen and 70% nitrous oxide. The vertebral arteries were irreversibly
occluded by electrocoagulation, and a small-diameter silicon tubing was
looped around the carotid arteries to facilitate subsequent occlusion. On
the following day, both carotid arteries were clamped with microvascular
clamps for 3 or 6 min in awake and spontaneously ventilating animals.
Rats lost their righting reflex within 1 min of carotid clamping. Cessation
of electroencephalographic activity was confirmed during ischemic in-
sults. Heartbeat, arterial blood pressure, and core temperature were
continuously monitored during surgery, ischemia, and drug administra-
tion. The body temperature of rats was supported with a heating blanket
during and in the hours after surgery, ischemia, and reperfusion. No
difference in body temperature, heartbeat, and arterial blood pressure
has been seen among the different groups.
Drug treatments. All drugs were freshly mixed on the day of experi-
mentation. KA (Sigma, St. Louis, MO) was dissolved in NaCl 0.9%
solution and injected intraperitoneally (5 and 7.5 mg/kg, i.p.). All rats
that were treated with KA exhibited seizures within the first hour after
injection. LIN was first dissolved in ethanol at a molar concentration and
then diluted in NaCl 0.9% solution to reach a final concentration of 500
mM. LIN500 (500 nmol/kg body weight, i.v.) was injected 3 d before KA
(7.5 mg/kg, i.p.) injection or 6 min ischemia. The pH of the different
solutions was adjusted to 7.0. The diethyldithiocarbamate (DTTC) (Sig-
ma) was dissolved in NaCl 0.9% solution and injected intraperitoneally
(150 mg/kg, i.p.) 15 min before LIN500 or KA5 administration or
sublethal 3 min ischemia.
Administration of kB decoy DNA. As reported previously (Smith-
Swintosky et al., 1994; Yu et al., 1999), double-stranded kB decoy DNA
was prepared by annealing complementary single-stranded oligonucleo-
tides of the following sequences: 59-GAGGGGACTTTCCCT-39 and
59-AGGGAAAGTCCCCTC-39. Control DNA with a scrambled se-
quence was prepared by annealing oligonucleotides of the following
sequences: 59-GATGCGTCTGTCGCA-39 and 59-TGCGACAGACG-
C1ATC-39. Stocks of double-stranded DNA were prepared at a concen-
tration of 2 mM in saline. kB decoy and control scrambled DNA (60 mg)
were infused intracerebroventricularly at a rate of 0.5 ml /min for 20 min
(two injections at 24 and 2 hr before sublethal 3 min ischemia or KA or
LIN500 treatment) via a stainless steel cannula (23 gauge) stereotaxically
implanted with a Kopf stereotaxic apparatus (David Kopf Instruments,
Tujunga, CA) into the right lateral ventricle (dorsoventral, 2 3.6 mm
below the cortical surface; mediolateral, 11.4 mm from bregma; and
anteroposterior, 2 0.8 mm from bregma) (Smith-Swintosky et al., 1994;
Yu et al., 1999).
Histolog ical procedures. At the end of the experiment, animals were
killed at designated time points, and brains were frozen quickly in
isopentane at 240°C. Coronal sections (10 mm) were cut on cryostat
(Leica, Nussloch, Germany) and post-fixed by immersion in 4% parafor-
maldehyde–10 22 M PBS for 30 min. Slides were then dehydrated in
ethanol baths (50, 70, and 100%), air dried, and stored at 270°C until
use. For each brain studied (n 5 6 per time point and treatment), two
sections were placed on 3-aminopropylethoxysilane-coated slides, and 10
slides (randomly chosen) per rat were stained with cresyl violet. The
neuronal density of hippocampal CA1 subfield, known to be the most
vulnerable to ischemia, was determined by the method of Kirino (1982)
on coronal sections of the dorsal hippocampus corresponding to brain
sections located between 3.14 and 4.16 mm posterior to bregma (Paxinos
and Watson, 1986). The total linear length of the CA1 sector was
measured using a digitizer. The number of living neurons in the stratum
pyramidale within the CA1 subfield was counted using a Leica Aris-
toplan photomicroscope at a magnification of 4003. Neurons that had
shrunken cell bodies with surrounding empty spaces were excluded. The
neuronal density of CA1 sector, i.e., the number of intact pyramidal cells
per 1 mm linear length of the CA1 stratum pyramidale observed in each
10 mm section, was quantified. Thus, a mean value for each hippocampal
CA1 substructure was obtained from 10 bilateral measurements on two
sections per slide and 10 slides per rat, for the six animals in each of
experimental group. The neuronal density for a given animal represents
the average of both right and left hippocampal neuronal cell densities.
Neuronal density values were expressed as mean 6 SEM. Data analysis
was performed by two-factor (experimental condition and brain region)
ANOVA, followed by Tukey’s w test for multiple comparisons. A prob-
ability ,5% was considered statistically significant.
Preparation of nuclear and cytosolic extracts. Nuclear and cytosolic
extracts from hippocampi were prepared according to the method re-
ported previously with some modifications (Dignam et al., 1983). Briefly,
after being removed from storage at 270°C, hippocampi (n 5 6 per
experimental group) were homogenized in four volumes of ice-cold lysis
buffer containing 10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 1%
NP-40, 0.5 mM dithiothreitol, and protease inhibitor cocktail on ice using
a Dounce homogenizer. After 10 min at room temperature, homogenates
were centrifuged at 6000 3 g for 5 min at 4°C. The supernatant was taken
as the crude cytosolic fraction. The pellet was resuspended in 10 vol of
cold washing buffer (20 mM HEPES, pH 7.9, 25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, and protease
inhibitor cocktail). After 30 min at 4°C, under continuous gentle mixing,
the extracted nuclear proteins were collected by centrifugation at
12,500 3 g for 30 min at 4°C. The supernatant was dialyzed 1 hr at 4°C
against 10 mM Tris, 10 mM MgCl2, 100 mM KCl, 1 mM EDTA, 1 mM
dithiothreitol, and protease inhibitor cocktail. This dialyzed supernatant
Blondeau et al. • NFkB Is a Key Event in Brain Tolerance J. Neurosci., July 1, 2001, 21(13):4668–4677 4669
was again centrifuged at 50,000 3 g for 30 min at 4°C. The pellet
resuspended in 20 mM HEPES, pH 7.9, 50 mM KCl, 0.2 mM EDTA, 0.2
mM dithiothreitol, and protease inhibitor cocktail was aliquoted and
stored at 270°C until use.
The crude cytosolic fractions were mixed with 1⁄10 vol cytosolic extrac-
tion buffer (0.3 M HEPES, pH 7.9, 0.03 mM MgCl2, 1.4 M KCl, 0.5 mM
dithiothreitol, and protease inhibitor cocktail) and centrifuged at
100,000 3 g for 1 hr at 4°C. The supernatant was dialyzed, centrifuged,
aliquoted, and stored at 270°C as described above. Protein concentra-
tions of the final nuclear and cytosolic fractions were determined by using
Bradford’s method (Bradford, 1976). Aliquots of the nuclear and cyto-
solic extracts were stored at 270°C for gel shifts, supershift assays, and
Western blottings.
Electrophoretic mobilit y shif t assay. The gel-shift assay was performed
using a commercial DNA-binding protein detection system (Promega,
Charbonnie´res, France), as described by the manufacturer. Briefly, double-
stranded oligonucleotide containing the kB consensus sequence (59-
AGTTGAGGGGACTTTCCCAGGC-39) was end-labeled using
[g- 32P]ATP (6000 Ci/mmol; ICN Biochemicals, Orsay, France) and T4
polynucleotide kinase and was purified by centrifugation through a G-25
spin column (Amersham Pharmacia Biotech, Saclay, France). DNA
binding was performed in 20 ml reaction containing a 20 mg aliquot of
extracted nuclear protein, 10 mM HEPES, pH 7.9, 50 mM KCl, 0.2 mM
EDTA, 2.5 mM DTT, 10% glycerol, and 0.05% NP-40. After 10 min of
incubation on ice, 3 3 10 24 cpm of labeled probe was added to the
reaction, and the mixture was incubated for 20 min at 37°C. Then,
protein–DNA complexes were resolved by electrophoresis through 4 or
7% native polyacrylamide gels (37.5:1 acrylamide/bisacrylamide) in
buffer containing 5 mM Tris, pH 8.3, and 38 mM glycine for 4 hr at 150 V.
Gels were dried, autoradiographed on a Bas-1500 phosphorimager (Fu-
jifilm, Tokyo, Japan) for 4 hr, and exposed to x-ray film (X-Omat;
Eastman Kodak, Le Pontet, France) using intensifier screens at room
temperature for 3 d. The specificity of the identified k-binding proteins in
the nuclear extracts was determined by adding a 50-fold excess of unla-
beled competitor to 20 mg of nuclear extract before incubation with the
binding mixture containing buffer and labeled probe. The transcription
factor AP2 consensus oligonucleotide (59-GATCGAACTGACCGCCCG
CGGCCCGT-39) was used as the unlabeled nonspecific competitor. To
ensure consistency in the data analysis, the nuclear and cytosolic extracts of
different experimental groups were run on the same gel.
To measure total NFkB activity in the cytosol, cytosolic extracts (20
mg) were treated after the DNA-binding reaction with deoxycholate
(DOC) at a final concentration of 0.5% for 5 min on ice, followed by
incubation in 1% NP-40 for 30 min at room temperature to release
NFkB from IkB.
For gel supershift experiments, the oligonucleotide–nuclear protein
binding reaction was followed by incubating the mixture overnight at 4°C
with 1 mg of either anti-p50 or anti-p65 antibodies (Santa Cruz Biotech-
nology, Tebu, France) separately or together. Electrophoretic mobility
shift assay (EMSA) was then performed as described above.
All radioactive gels were quantified by densitometry using a Bas-1500
phosphorimaging system (Fujifilm) and TINA software. Data are ex-
pressed as mean 6 SEM (n 5 6). Data analysis was performed by
two-factor ANOVA, followed by Tukey’s w test for multiple compari-
sons. A probability ,5% was considered statistically significant.
Western blotting. Proteins in the nuclear and cytosolic extracts (20 mg)
were separated by SDS-PAGE on 10% SDS-PAGE gels for 1 hr at 100
mA. Proteins were transferred onto nitrocellulose membrane
(Hybond-C) in blotting buffer (156 mM Tris, 1 M glycine, and PBS) for 2
hr at 50 mA and blocked with 4% skim milk (Regilait) in PBS for 2 hr at
room temperature. The blotted membrane was incubated for 4 hr at
room temperature with the rabbit polyclonal anti-NFkB p65 antibody
(AB1604, diluted 1:2000; Chemicon, Euromedex, Mundolsheim, France)
and overnight at 4°C with the mouse monoclonal antibody raised against
the active form of NFkB (MAB3026, diluted 1:150; Chemicon) or the
rabbit polyclonal anti-IkBa antibody (sc-847, diluted 1:500; Santa Cruz
Biotechnology). After washing with 0.1% Tween 20–PBS (four times, 15
min each), the blots were incubated for 1 hr at room temperature with
goat anti-rabbit IgG coupled to horseradish peroxidase (diluted 1:15,000;
Jackson ImmunoResearch, Interchim, Montluson, France) and then
washed again in 0.1% Tween 20–PBS. Fluorography was performed on
Kodak X-Omat AR film using Western blotting detection reagents
(Pierce, Rockford, IL) following the enhanced chemiluminescence tech-
nique. To ensure consistency in the data analysis, the nuclear and
cytosolic extracts of the same sample were run on the same gel (n 5 6).
In each blot, a-tubulin was used as an internal control for the loading of
protein level (data not shown).
Immunohistochemistry. Frozen sections (10 mm) were post-fixed with
acetone for 10 min at 220°C. Sections were then immersed in 0.3%
H2O2–methanol for 30 min, permeabilized in 0.3% Tween 20–PBS for 15
min, treated for 10 min in a microwave oven in 0.1 M citrate buffer, pH
6.0, and blocked with 1% horse–goat serum (Vector Laboratories, Bur-
lingame, CA) for 4 hr at room temperature. Sections were then incubated
with the mouse monoclonal antibody raised against the active form of
NFkB (MAB3026, diluted 1:150; Chemicon) overnight at 4°C. After the
primary incubation and three rinses in 13 PBS, sections were then
incubated in biotinylated horse anti-mouse IgG or biotinylated goat
anti-rabbit IgG (diluted 1:1000; Jackson ImmunoResearch) for 2 hr.
NFkB labeling was compared with immunohistochemical stainings ob-
tained with the monoclonal mouse antibody against the neuron-specific
nuclear protein NeuN (neuronal nuclei) (MAB377, diluted 1:250;
Chemicon), the rabbit anti-cow glial fibrillary acidic protein (GFAP)
marker of astrocytes (clone V9, diluted 1:250; Dako, Trappes, France),
the monoclonal mouse anti-vimentin (Z0334, diluted 1:50; Dako), and
the monoclonal mouse anti-RT1B directed against the Class II major
histocompatibility complex (MRC OX6, diluted 1:50; Biosource Interna-
tional, Cliniscience Montrouge, France), markers of activated microglia.
Immunohistochemical expressions were visualized by DAB–DAB-Ni
staining using the VectaStain ABC kit (Vector Laboratories). All sec-
tions were washed in distilled water and mounted with Entellan. For
double labeling, the monoclonal mouse antibody against NeuN
(MAB377, diluted 1:250; Chemicon) and the rabbit polyclonal anti-
NFk-B p65 subunit antibody (AB1604, diluted 1:150; Chemicon) were
used and detected with the Alexa Fluor 488 goat–horse anti-rabbit–anti-
mouse IgG antibodies (diluted 1:1000; Molecular Probes, Interchim,
Montluson, France). Sections were analyzed using a laser-scanning con-
focal microscope (Leitz, Wetzlar, Germany).
RESULTS
Effect of preconditioning on NFkB DNA-binding activity
and subcellular localization of p65 and p50 subunits
(Western blotting and immunohistochemistry)
Figure 1 demonstrates that the three different preconditioning
stimuli (sublethal 3 min ischemia, KA5 treatment, or LIN500
treatment) were associated with activation of NFkB. The gel-shift
analysis (EMSA) of NFkB DNA-binding proteins at 1, 24, and 72
hr after ischemia or after treatment in hippocampal nuclear
extracts from rats subjected to 3 min ischemia or injected with
KA5 or LIN500 was compared with that obtained from controls
(sham-operated or vehicle-injected). As illustrated in Figure 1, A
and B, each preconditioning stimulus induced an intense NFkB
DNA-binding activity as early as 1 hr after sublethal ischemia,
KA5 treatment, or LIN500 treatment in pooled nuclear hip-
pocampal tissue. Figure 1B summarizes the quantification of
NFkB binding activity in nuclear extracts from the complete set
of rats. For the three preconditioning stimuli, the increase in
NFkB DNA-binding activity in the nuclear fraction varied from
5.4- to 9.7-fold compared with respective control groups. The
specificity of the NFkB binding was demonstrated by a compet-
itive experiment using unlabeled NFkB oligonucleotide probe
and nonspecific transcription factor AP2 oligoprobe and per-
formed on nuclear extracts from rats submitted to 3 min ischemia
or treated with LIN500 or KA5. Competition assays using excess
of nonradiolabeled NFkB-specific oligoprobe extinguished the
specific retarded NFkB band, whereas the nonspecific competitor
AP2 oligoprobe has no effect. Furthermore, supershift assays
showed that the NFkB complex was composed predominantly of
p65/p50 heterodimers under all conditions. Figure 1C gives one
example of supershift assay obtained with a preconditioning in-
duced by a sublethal 3 min ischemia. Figure 1C shows the marked
slowing down of the migration of the NFkB–oligonucleotide
complex (supershift) after the addition of specific anti-p50 and
p65 antibodies to the EMSA reaction mixture. A combination of
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anti-p65 and anti-p50 antibodies caused additional gel retardation
and reduced the NFkB DNA band (Fig. 1C). Similar results were
obtained with KA5 or LIN500 treatment preconditioning stimu-
lus (data not shown).
Figure 2 depicts the induction of NFkB protein in the hip-
pocampus after the three types of preconditioning assessed using
Western blot analysis (Fig. 2A–C) and immunohistochemistry
(Fig. 3). Figure 2A–C shows representative Western blotting
analysis of the p65 (Fig. 2A,B) and p50 (Fig. 2C) content in
cytosolic and nuclear extracts from rats subjected to 3 min isch-
emia or injected with 5 mg/kg KA or 500 nmol/kg LIN taken at
serial times after sublethal or drug treatments. The p65 and p50
subunits of NFkB were rich in the cytosolic fractions from sham-
operated or vehicle-injected rats but undetectable in the nuclear
extracts. In contrast, the protein levels of p65 and p50 in the three
preconditioned groups were significantly enhanced in the nuclear
fraction and concurrently decreased in the cytosol as early as 1 hr,
indicating a rapid translocation of these NFkB subunits from the
cytosol to the nucleus.
Immunostaining using a monoclonal antibody raised against
the active form of NFkB performed at 24 hr after each of
different preconditioning triggers (short ischemia, KA5 treat-
ment, or LIN500 treatment) was performed to determine the
cellular identity of the increase in NFkB activity associated with
preconditioning visualized above by gel shift and Western blot-
ting analysis (Figs. 1, 2A–C). Immunoreactivity for the activated
form of NFkB was not detectable in either sham-operated (Fig.
3Ba,Bb) or vehicle-injected (data not shown) hippocampus. Sub-
lethal 3 min ischemia (Fig. 3Ac,Ad), KA5 treatment (Fig.
3Ca,Cb), or LIN500 treatment (Fig. 3Da,Db) induced a strong
immunoreactivity for NFkB in CA1 and CA3 pyramidal cell
layers (Fig. 3Ac,Ad,Ca,Cb,Da,Db), hilar neurons, and dentate
gyrus (data not shown) 24 hr after preconditioning stimulus. The
extent and intensity of immunoreactivity appeared similar in
three treatments. According to morphological criteria, the posi-
tive cells seemed to be neurons. Immunohistochemical observa-
tions with GFAP and vimentin antibodies excluded astrocytes
and microglia as main sources of NFkB activation in the three
models of preconditioning tested (data not shown). Immunostain-
Figure 2. Representative Western blotting analysis of p65 and p50 sub-
units of NFkB in nuclear (A, C) and cytosolic (B) extracts from hip-
pocampi of control rats ( C) or rats submitted to 3 min ischemia (I3) or
treated with KA5 or LIN500 and obtained at 1, 24, and 72 hr after the
different preconditionings.
Figure 1. EMSA showing the time
course of increased NFkB DNA-
binding activity induced by the three
different preconditionings (3 min isch-
emia, KA5 treatment, and LIN500
treatment). A, Representative gel shifts
analysis showing NFkB DNA-binding
activity in nuclear protein extracts from
hippocampi of control rats (lane 1) or
rats submitted to 3 min ischemia (lanes
5–9) or treated with KA5 (lanes 2–4 ) or
LIN500 (lanes 10–12) and obtained at 1,
24, and 72 hr after the different precon-
ditionings. NFkB DNA-binding activity
was assayed as described in Materials
and Methods. Competition assays of
NFkB DNA-binding activity was per-
formed in the presence of 50-fold excess
of unlabeled competitor NFkB (lane 9)
and nonspecific competitor AP2 (lane 8)
consensus oligonucleotides. The shifted
bands of specific NFkB DNA complexes
are indicated by the arrowheads. The
right and lef t gels correspond to 4 and
7% polyacrylamide gels, respectively. B,
Quantification of NFkB DNA-binding activity in the different experimental groups. The specific shifted bands were quantified using a phosphorimaging
system as described in Materials and Methods. The values are expressed as a percentage of control. No significant differences were found between
vehicle-injected and sham-operated rats, and values of these groups were pooled and termed control. Data represent the mean 6 SEM values. Data are
representative of six separate experiments in each group (n 5 6). *p , 0.05 indicates statistical significance when compared with control. C, Supershift
analysis of NFkB binding proteins present in nuclear extracts 24 hr after 3 min ischemia. The binding activity assay was performed in the presence of
anti-p65 antibodies, anti-p50 antibodies, a combination of both, or no antibody. The arrowheads indicate the bands of specific NFkB–DNA complexes,
which were supershifted by anti-p65 antibodies, anti-p50 antibodies, or by their combination.
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ings obtained with the antibody raised against the neuron-specific
nuclear protein NeuN (Fig. 3Aa,Ab) provided evidence that the
immunoreactivity for the active form of NFkB was predominant
in the nucleus. Double labeling with antibodies against the
neuron-specific nuclear protein NeuN and the NFkB-p65 subunit
indicated nuclear colocalization (Fig. 3Ea,Eb).
Effects of kB decoy DNA and DTTC on NFkB DNA-
binding activity and subcellular localization of
p65 subunit
kB decoy DNA and DTTC have been shown to block NFkB
DNA-binding activity in different systems (Schreck et al., 1992;
Smith-Swintosky et al., 1994; Yu et al., 1999). In the present
study, double-stranded kB decoy DNA or control double-
stranded DNA with a scrambled sequence was injected intracere-
broventricularly (two injections at 24 and 2 hr before 3 min
ischemia, KA5 treatment, or LIN500 treatment), and rats were
killed 1 hr after the preconditioning stimulus. As illustrated in
Figure 4, A and B, the gel-shift analysis of NFkB shows that the
increase in NFkB DNA-binding activity induced by each precon-
ditioning was suppressed in hippocampus of rats injected with kB
decoy DNA but was unaffected in animals injected with control
scrambled DNA. Figure 4B summarizes the quantification of
NFkB DNA-binding activity in nuclear extracts from the com-
plete set of rats. For the three preconditioning stimuli, the de-
crease in NFkB DNA-binding activity in the nuclear fraction
varied from 4.8- to 6.0-fold compared with respective control
groups (KA5, LIN500, or I3). The remaining NFkB DNA-
binding activity corresponded to that of negative controls
(vehicle-injected or sham-operated rats). Administration of kB
decoy DNA prevented the decrease in p65 content in the cytosolic
extracts (data not shown) and its increase induced by sublethal
ischemia (I3) or LIN500 treatment in the nuclear extracts ana-
lyzed 24 hr after the preconditioning stimulus (Fig. 4C). A similar
result was obtained with KA5 treatment preconditioning stimulus
(data not shown).
In the same manner, administration of DTTC (150 mg/kg, i.p.)
15 min before 3 min ischemia, KA5 treatment, or LIN500 treat-
ment significantly blocked the increase in NFkB DNA-binding
activity in the nuclear fraction of hippocampi analyzed 24 hr after
sublethal ischemia or drug treatment (KA5 or LIN500) (Fig.
4A,B). Analysis of extracts from rats pretreated with DTTC and
then exposed to the different preconditioning stimuli showed a
greatly reduced level of p65 content in nuclear fraction compared
with hippocampi submitted to 3 min ischemia or injected with
LIN500 in the absence of DTTC (Fig. 4C). A similar result was
obtained with KA5 treatment preconditioning stimulus (data not
shown).
Effects of kB decoy DNA and DTTC treatment on the
hippocampal ischemic tolerance induced by the
different preconditionings
The effects of kB decoy DNA and DTTC treatment on brain
tolerance were assessed by analysis of the neuronal degeneration
in CA1 substructure of rats killed 7 d after the second ischemia.
Figure 5, A and C, shows representative photomicrographs of the
CA1 sector in the different groups, and Figure 5, B and D, reports
the quantitative analysis of neuronal cell density in the respective
experimental groups. As expected, control (sham-operated or
vehicle-injected) rats did not show neurodegeneration (Fig. 5Aa).
In contrast, typical cell death appeared in pyramidal neurons of
CA1 substructure after 6 min ischemia (Fig. 5Ab,Cb). Compared
with control rats (Fig. 5Ba,Da), 21% of CA1 pyramidal cells only
survived (Fig. 5Bb,Db). Preconditioning with sublethal 3 min
ischemia (Fig. 5Ac) or LIN500 injection (Fig. 5Cc) 3 d before 6
min ischemia totally prevented neuronal death induced by severe
ischemia. In these preconditioned groups, 99 and 95% of CA1
cells were preserved, respectively (Fig. 5Bc,Dc). However, the
intracerebroventricular administration of kB decoy DNA before
each preconditioning stimulus (3 min ischemia or LIN500 treat-
ment) abolished the ischemic tolerance and markedly enhanced
the hippocampal neurodegeneration (Fig. 5Ad,Cd) compared
with rats that were injected with scrambled control DNA before
preconditioning (Fig. 5Ae,Ce). The injection of kB decoy DNA
alone did not induce any damage in hippocampus (Fig. 5Cg,Dg).
In the same manner, the intraperitoneal injection of DTTC be-
fore 3 min ischemia (Fig. 5Af) or LIN500 treatment (Fig. 5Cf)
blocked the ischemic tolerance induced by each preconditioning.
Quantitative analysis of neuronal damage in CA1 substructure
confirmed the marked enhancement of CA1 pyramidal cell de-
generation in rats injected with kB decoy DNA before each
preconditioning stimulus (Fig. 5Bd,Dd) compared with rats sub-
mitted to 6 min ischemia (Fig. 5Bb,Db). Seventy and 75% of CA1
pyramidal neurons were destroyed in rats injected with kB decoy
DNA before sublethal 3 min ischemia (Fig. 5Bd) or LIN500
injection (Fig. 5Dd), respectively. Similar results were obtained
with epileptic tolerance (data not shown). Together, these data
show that the treatment with kB decoy DNA or DTTC prevented
the neuroprotective effects of late preconditionings (sublethal
Figure 3. Representative immunohistochemical staining of the active
form of NFkB protein in hippocampal CA1 and CA3 substructures of rats
killed 24 hr after each of preconditioning stimuli. Aa–Ad, 3 min ischemia.
Ba, Bb, Sham-surgery. Ca, Cb, KA5 treatment. Da, Db, LIN500 treat-
ment. Aa, Ab, Immunohistochemical staining of NeuN protein within
CA1 and CA3 pyramidal cells after sublethal ischemia. E, Colocalization
of NFkB-p65 and the neuron-specific nuclear protein NeuN (neuronal
nuclei) within CA1 (Ea) and CA3 (Eb) pyramidal cells. Brain sections
were immunostained with antibodies against the p65 subunit of NFkB
( green) and NeuN (red) for double-labeling. Scale bars, 20 mm.
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ischemia, LIN500 treatment, or KA5 treatment) against ischemia
or epilepsy and that the blockade of NFkB activation was dele-
terious in the three models of brain tolerance used in that work.
Changes in NFkB DNA-binding activity and subcellular
localization of IkBa and the active form of p65 in the
different groups of preconditioned brains
Electrophoretic mobility shift assays revealed that NFkB DNA-
binding activity was decreased in nuclear extracts of rats precon-
ditioned with 3 min ischemia, KA5 treatment, or LIN500 treat-
ment compared with rats submitted to 6 min ischemia or treated
with 7.5 mg/kg KA (Fig. 6A). Treatment with DOC, which
dissociates the cytosolic NFkB–IkB complex, allowing the detec-
tion of inactive NFkB, restored NFkB DNA-binding activity in
preconditioned hippocampi (Fig. 6A). This indicated that NFkB
was present but not active in preconditioned rats. Figure 6B
summarizes the quantification of NFkB DNA-binding activity in
nuclear and cytosolic extracts from the complete set of rats. For
the three preconditioned groups, the NFkB DNA-binding activ-
ity in nuclear extracts decreased 44–65% compared with respec-
tive positive controls. The restoring of the NFkB DNA-binding
activity after DOC treatment in cytosolic extracts reached 90%
compared with positive controls (Fig. 6B). A possible mediator of
the inhibitory action of preconditioning on NFkB activation is
IkB, encoded by the immediate early gene MAD-3 (Haskill et al.,
1991). IkB degradation is enhanced by various NFkB inducers,
which also cause new synthesis of IkBa by an inducible autoreg-
ulatory pathway (Sun et al., 1993). The effect of preconditioning
on IkBa and NFkB metabolism was examined by immunoblotting
with antibodies to IkBa and active form of NFkB, which recog-
nizes the heterotetrameric protein, consisting of the two p50 and
two p65 subunits. Analysis of nuclear and cytosolic extracts of
control, ischemic, or epileptic rats revealed that the loss of IkBa
correlated with translocation of NFkB from the cytoplasm to the
nucleus (Fig. 6C). Severe ischemia and KA treatment (7.5 mg/kg)
led to the disappearance of IkBa and to the presence of the active
form of NFkB in cytosolic extracts. In contrast, the amount of
IkBa protein was notably increased in nuclear extracts of rats
preconditioned with LIN500 treatment (LIN500-I6 or LIN500-
KA7.5) and submitted to severe 6 min ischemia or KA7.5 treat-
ment 3 d later (Fig. 6C). A similar result was obtained with rats
preconditioned with 3 min ischemia or KA5 treatment (data not
shown). The profile of preconditioning-induced IkBa and of the
accumulation of the active form of NFkB paralleled that of the
inhibition of NFkB DNA-binding activity. Preconditioning with 3
min ischemia, KA5 or LIN500 treatment resulted in retention of
p65 in cytoplasm (data not shown).
DISCUSSION
Many different mechanisms have been proposed to be involved in
the development of brain tolerance, including adenosine receptor
stimulation, KATP channel opening, and delayed expression of
neuroprotective genes. However, little is known on the nature of
events occurring between the early opening of KATP channels
through adenosine receptors and the induction of neuroprotec-
tive genes within the time window of protection-promoting neu-
ronal survival. The switching “on–off” of gene expression is the
province of transcription factors, which operate singly or in asso-
ciation with other proteins. The present work provides the first
demonstration of the key role of the NFkB transcription factor in
the signal transduction cascade of brain tolerance. The NFkB
proteins are a family of inducible transcription factors that acti-
vate a variety of cellular genes involved in control of the inflam-
matory response and in regulating cellular growth (Mattson et al.,
2000). The NFkB signaling pathway is a major determinant in the
Figure 4. Electrophoretic mobility shift as-
say (A, B) and Western blotting analysis of
p65 subunit of NFkB (C) showing the effect
of intracerebroventricular administration of
kB decoy DNA or intraperitoneal injection
of DTTC on the increased NFkB DNA-
binding activity induced by the three differ-
ent preconditionings (3 min ischemia, KA5
treatment, and LIN500 treatments). A,
Representative gel shift analysis showing
NFkB DNA-binding activity in hippocam-
pal nuclear extracts isolated from rats that
had received intracerebroventricular injec-
tions of vehicle, 60 mg of kB decoy DNA
(kBdecoy), 60 mg of scrambled control DNA
(ScDNA), or intraperitoneal injection of
DTTC (150 mg/kg) before sublethal isch-
emia (I3) or administration of either KA5
or LIN500. Rats were killed 1 hr (for kB
decoy or scrambled control DNA) or 24 hr
(for DTTC) after each type of precondi-
tioning. NFkB activity was assayed as de-
scribed in Materials and Methods. The
shifted band of specific NFkB DNA com-
plexes is indicated by the arrowhead. B,
Quantification of NFkB DNA-binding ac-
tivity in the different experimental groups. The specific shifted bands were quantified using a phosphorimaging system as described in Materials and
Methods. Values are expressed as a percentage of control. Results are expressed as mean 6 SEM. Data are representative of six separate experiments
in each group (n 5 6). *p , 0.05 indicates statistical significance when compared with vehicle-injected rats. C, Representative Western blotting analysis
of p65 subunit of NFkB in hippocampal nuclear extracts isolated from rats that had received intracerebroventricular injections of vehicle, 60 mg
of kB decoy DNA (kBdecoy), 60 mg of scrambled control DNA (ScDNA) or intraperitoneal DTTC injection (150 mg/kg) before I3 or LIN500. Rats
were killed 24 hr after the conditioning stimulus. The position of p65 is indicated by the arrowhead. 1, Vehicle; 2, DTTC–LIN500; 3, LIN500; 4,
Sham-operated; 5, I3; 6, DTTC–I3; 7, scrambled control DNA–LIN500; 8, kB decoy DNA–LIN500; 9, kB decoy DNA–I3; 10, scrambled control
DNA–I3.
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control of neuronal death and/or cell survival. Although NFkB
activation occurs in neurons after brain injury, its role in the
injury outcome remains unclear. The assumption that NFkB is
contributing to neuronal cell death is documented by many pa-
pers reporting increased NFkB activity under pathological con-
ditions in which neurons were dying (Grilli et al., 1996; Clemens
et al., 1997). However, subsequent in vitro studies provide evi-
dence that the activation of NFkB can protect neurons against
amyloid b-peptide toxicity (Barger et al., 1995) and excitotoxic or
oxidative stress (Goodman and Mattson, 1996; Mattson et al.,
1997). Previous studies, in which injury-induced NFkB activity
was suppressed by gene deletion of the p50 subunit (Yu et al.,
1999) or administration of kB decoy DNA (Mattson et al., 1997;
Yu et al., 1999) or pharmacological agents (Taglialatela et al.,
1997; Maggirwar et al., 1998), strongly support a neuroprotective
role for NFkB activation. NFkB consists of a p50 and p65/RelA
complex that is trapped in the cytoplasm by an inhibitory protein
IkBa (Verma et al., 1995; Baeuerle and Baltimore, 1996). As long
as IkBa is bound to the p50/p65 complex, its translocation to the
nucleus is prevented. Activation of NFkB consists of phosphor-
ylation or degradation of IkBa from the complex in the cyto-
plasm, and during activation NFkB is translocated to the nucleus
of the cell (Chen et al., 1995; Verma et al., 1995; Baeuerle and
Baltimore, 1996).
Results reported in this paper demonstrate that, in the three
models of brain tolerance studied (ischemic, epileptic, and poly-
unsaturated fatty acid-induced preconditionings), the activation
of NFkB was required for the development of late cerebral
preconditioning against severe ischemia or epilepsy. The three
different inducers of preconditioning (sublethal 3 min ischemia,
KA5 treatment, or LIN500 treatment) induced rapid activation
of NFkB, as evidenced by its increased DNA-binding activity and
nuclear translocation. The gel-shift analyses revealed that DNA-
binding activity increased as early as 1 hr after sublethal ischemia,
KA5 treatment, or LIN500 treatment, and the shifted band con-
sisted of p50/p65 heterodimers. The presence of active NFkB was
confirmed by nuclear localization of p50 and p65 subunits in
Western blots of hippocampal extracts as early as 1 hr after each
preconditioning stimulus, indicating a rapid translocation of
NFkB subunits from cytosol to the nucleus. Immunohistochem-
ical analyses using p65 antibodies revealed that, 24 hr after each
of preconditioning stimuli, NFkB activation occurred in the py-
ramidal neurons and not in the glial cells. Pretreatment with the
NFkB inhibitor DTTC or kB decoy DNA blocked the increased
DNA-binding activity and the nuclear translocation of NFkB
and, at the same time, abolished the neuroprotective effects of
different delayed preconditionings against severe ischemia or
epilepsy. Previous studies have shown that kB decoy DNA can
block activation of kB-responsive genes, greatly increase the
vulnerability of neurons to different insults, and promote neuro-
nal cell death (Mattson et al., 1997; Yu et al., 1999). Dithiocar-
bamates, such as DTTC, have also been reported to be potent
inhibitors of NFkB activation in various cell types (Schreck et al.,
1992; Sherman et al., 1993; Ziegler-Heitbrock et al., 1993). To-
gether, these results indicate that activation of NFkB is an essen-
tial mechanism whereby sublethal ischemia, KA5 treatment, or
LIN500 treatment results in delayed neuroprotection.
The present work also provides evidence that the inhibition of
NFkB observed in rats preconditioned with 3 min ischemia, KA5
treatment, or LIN500 treatment compared with ischemic or epi-
leptic controls was correlated with the prevention of the inducible
degradation of IkBa. Treatment of preconditioned extracts with
the detergent DOC, which revealed as much DNA-binding activ-
ity in the different preconditioned hippocampi as in the controls,
indicated that NFkB was present but not active in the precondi-
tioned extracts. The preconditioning also prevented the release of
NFkB from IkBa after a severe ischemic or epileptic insult. The
phosphorylation and degradation of IkBa is necessary for the
activation of NFkB and its subsequent appearance in the nucleus
Figure 5. Effect of kB decoy DNA, scrambled control DNA, and DTTC
injections on the ischemic tolerance induced by brief ischemia or LIN500
treatment. A, C, Representative photomicrographs highlighting morpho-
logical changes in CA1 subfield of cresyl violet-stained hippocampal
sections 7 d after severe 6 min ischemia in the different experimental
groups. I6 corresponds to rats submitted to 6 min ischemia. I3-I6 corre-
sponds to rats submitted to 3 min ischemia 3 d before 6 min ischemia.
kdecoy I3-I6 or ScDNA I3-I6 corresponds to rats that, respectively, had
received intracerebroventricular injections of 60 mg of kB decoy DNA or
scrambled control DNA at 24 and 2 hr before 3 min ischemia. DTTC I3-I6
corresponds to rats that had received an intraperitoneal injection of
DTTC (150 mg/kg) 30 min before 3 min ischemia. Rats were killed 7 d
after 6 min ischemia. Scale bar, 100 mm. B, D, Quantification of neuronal
density in the hippocampal CA1 pyramidal layer of different experimental
groups. Results are expressed as mean 6 SEM (n 5 6) and represent
neuronal densities assessed in cresyl violet-stained sections per 1 mm
linear length of CA1 pyramidal layer. A mean value for each CA1
substructure was obtained from 10 bilateral measurements on two sections
per slide and 10 slides per animal (n 5 6) in each of the experimental
groups. Differences were considered statistically significant when p , 0.05
(Tukey’s test). * indicates significantly different from control (sham-
operated animals). # indicates significantly different from ischemic ani-
mals (6 min).
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(Chen et al., 1995; Verma et al., 1995; Baeuerle and Baltimore,
1996). Therefore, on activation of NFkB, IkBa concentrations
decrease. Immunoblotting with an antibody raised against IkBa
reveals that the amount of IkBa protein increased in the
preconditioned hippocampi compared with ischemic or epilep-
tic cytosolic extracts. An interesting observation is the pres-
ence of IkBa protein and the active form of NFkB in the
nuclear hippocampi of rats preconditioned with 3 min isch-
emia, KA5 treatment, or LIN500 treatment compared with
ischemic or epileptic controls, in which IkBa protein was
absent. The increase in IkBa abundance in preconditioned rats
is probably the result of increased IkBa synthesis. This result
strongly suggests that the inhibition of NFkB activation in-
duced by preconditioning is mediated by induction of the IkBa
inhibitory protein, which traps activated NFkB in inactive
cytoplasmic complexes. In accordance with previous work,
demonstrating the direct transcriptional activation of IkBa by
NFkB itself (Scott et al., 1993; Sun et al., 1993; Chiao et al.,
1994), IkBa probably newly synthetized after the activation of
NFkB by preconditioning stimulus will bind free cytoplasmic
NFkB and inactivate its potential nuclear translocation. Fur-
thermore, excess IkBa translocates to the nucleus by an un-
known mechanism, in which, as shown in vitro, it can sequester
free NFkB (p65), promote net dissociation of DNA-bound
NFkB, and thereby terminate its activity (Arenzana-Seisdedos
et al., 1995). This nuclear NFkB–IkBa complex may be trans-
ported back to the cytoplasm or degraded in the nucleus.
Recently, it has been shown that immunosuppression by glu-
cocorticoids may be the direct outcome of the inhibition of
NFkB activity through induction of IkBa synthesis (Auphan et
al., 1995; Scheinman et al., 1995). It is not excluded that such
a mechanism is also involved in the anti-inflammatory re-
sponse and neuroprotection induced by sodium salicylate and
aspirin (Kopp and Ghosh, 1994; Grilli et al., 1996).
In conclusion, these findings demonstrate that the transcription
factor NFkB is indeed at the crossing of neuronal cell death and
survival pathways and is a crucial component of the signal trans-
duction cascade of cerebral preconditioning. This paper shows
that (1) the three preconditioning protocols induce a rapid neu-
roprotective activation of NFkB in hippocampus, (2) the in-
creases in NFkB DNA-activity determined by gel shift and West-
ern blot analysis specifically reflect increases in hippocampal
neurons, (3) preconditioning the brain with sublethal ischemia,
KA5 treatment, or LIN500 treatment inhibits the activation of
NFkB after the second injury and renders the brain more resis-
tant to a subsequent potentially lethal ischemic or epileptic insult,
and (4) the inhibition of NFkB is mediated by induction of the
IkBa inhibitory protein, which traps activated NFkB in inactive
cytoplasmic complexes. The cellular mechanisms whereby the
three preconditioning treatments activate NFkB remains to be
identified. Nitric oxide and free hydroxyl radicals are potential
candidates for the role of NFkB activators. Not only they are
known to activate NFkB but they are also known to be involved
in brain and heart tolerance (Bolli et al., 1997; Centeno et al.,
1999; Xuan et al., 1999; Rauca et al., 2000). The neuroprotection
induced by activation of NFkB in hippocampal neurons related to
induction of MnSOD (Mattson et al., 1997) and the increase of
MnSOD activity in brain tolerance (Toyoda et al., 1997) strongly
support the link between NFkB and oxidative stress in cerebral
preconditioning. Together, these results strongly suggest that,
whatever the type of preconditioning, the initial signals elicited by
the conditioning stimulus are transduced into protective changes
via an NFkB-dependent mechanism. The crucial involvement of
Figure 6. Changes in NFkB DNA-binding
activity and subcellular localization of IkBa
and active form of NFkB in the different
groups of preconditioned brains. A, Repre-
sentative gel shifts analysis showing NFkB
DNA-binding activity in hippocampal nu-
clear and cytosolic extracts isolated from
rats preconditioned with 3 min ischemia
(I3-I6 ), KA5 treatment (K A5-K A7.5), or
LIN500 treatment (LIN500-I6 or LIN500-
K A7.5) and submitted to 6 min ischemia or
KA7.5 treatment 3 d later. Rats were killed
24 hr after the last treatment. Cytosolic
extracts were analyzed by EMSA with DOC
treatment after binding as described in Ma-
terials and Methods. The shifted band of
specific NFkB–DNA complexes is indi-
cated by the arrowhead. B, Quantification of
NFkB DNA-binding activity in the differ-
ent experimental groups. The specific
shifted bands were quantified using a phos-
phorimaging system as described in Mate-
rials and Methods. The values are expressed
as a percentage of control. No significant
differences were found between saline-
injected and sham-operated rats, and values
of these groups were pooled and termed
control. Results are expressed as mean 6
SEM. Data are representative of six sepa-
rate experiments in each group (n 5 6).
Differences were considered statistically significant when p , 0.05 (Tukey’s test). * indicates significantly different from control (saline-injected or
sham-operated animals). # indicates significantly different from KA7.5-injected animals. $ indicates significantly different from ischemic animals (6 min).
C, Representative Western blotting analysis of IkBa and active form of NFkB in hippocampal nuclear and cytosolic extracts isolated from ischemic (I6 )
and epileptic (K A7.5) rats and rats preconditioned with LIN500 treatment (LIN500-I6 or LIN500-K A7.5) and submitted to severe 6 min ischemia or
KA7.5 treatment 3 d later. Rats were killed 24 hr after the last treatment. The positions of IkBa and active form of NFkB are indicated by the arrowheads.
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this transcription factor in brain tolerance may open new ways in
the search of therapeutic strategies.
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